Loading…
Bio-Techne Corporation is projected to rise to $50.64 by 2027, a +5% move from its current price of $48.09. TECH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $46.84 | $48.11 | $49.40 | +0.03% |
| May 30 | $46.35 | $48.12 | $49.97 | +0.07% |
| May 31 | $45.97 | $48.14 | $50.41 | +0.10% |
| Jun 1 | $45.66 | $48.15 | $50.78 | +0.13% |
| Jun 2 | $45.39 | $48.17 | $51.12 | +0.17% |
| Jun 3 | $45.15 | $48.19 | $51.43 | +0.20% |
| Jun 4 | $44.93 | $48.20 | $51.72 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $44.93 | $48.20 | $51.72 | +0.23% |
| Week 2 | $43.74 | $48.32 | $53.37 | +0.47% |
| Week 3 | $42.87 | $48.43 | $54.70 | +0.70% |
| Week 4 | $42.17 | $48.54 | $55.88 | +0.94% |
| Week 5 | $41.57 | $48.65 | $56.94 | +1.17% |
| Week 6 | $41.05 | $48.77 | $57.94 | +1.41% |
| Week 7 | $40.58 | $48.88 | $58.88 | +1.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation (TECH) operates in the Healthcare sector as a life sciences company. The current price is $48.21 with a market cap of $7.55B, and it is ranked 1075 by market capitalization. The forecast shows a bullish long-term path, with average prices rising from $48.21 in 2026 to $262.02 by 2050 and a max price up to $491.21 in 2050.
The implied ROI grows from 0% in 2026 to 443.5% by 2050.
The asset is projected to move higher over the long run, with yearly averages stepping up across the horizon and a rising maximum price, signaling meaningful upside potential despite near-term volatility.
A major floor 30.6% below — a decisive break under it would weaken the trend.
The nearest floor, 10.0% below — buyers have tended to step in here.
The nearest ceiling, 26.0% above — a clean break opens room to run.
A major ceiling 48.4% above — clearing it would confirm fresh momentum.
Key TECH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TECH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $47.67 | Buy | $47.55 | Buy |
| MA 10 | $46.12 | Buy | $47.46 | Buy |
| MA 20 | $48.82 | Sell | $48.76 | Sell |
| MA 50 | $52.24 | Sell | $51.89 | Sell |
| MA 100 | $57.04 | Sell | $54.57 | Sell |
| MA 200 | $57.58 | Sell | $56.72 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.50 | Neutral |
| Stoch RSI (14) | 98.53 | Sell |
| CCI (20) | -15.35 | Neutral |
| Williams %R (14) | -37.06 | Info |
| MACD (12,26,9) | 0.30 | Buy |
| ROC (12) | -0.56 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 62.94 | Neutral |
| TRIX (15) | -0.62 | Sell |
| Awesome (5,34) | -4.47 | Sell |
| Ultimate (7,14,28) | 75.22 | Sell |
| Momentum (10) | 0.67 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 48.88 | Sell |
| ADX (14) | 17.93 | Neutral |
| ATR (14) | 1.34 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 50, with near-term momentum balanced.
The 30-day range spans $40.01 to $58.08, indicating a broad trading band around the current level.
Near-term technicals show the SMA50 at $52.31 and the SMA200 at $57.60, with near-term support at $43.30 and resistance at $60.58. The stock carries high volatility, reflected in the annualized volatility of 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $43.30 | $48.09 | $60.19 | 0% | Neutral | |
| $40.27 | $50.64 | $67.42 | +5% | Neutral | |
| $43.59 | $56.29 | $77.59 | +17% | Neutral | |
| $49.77 | $65.70 | $93.10 | +37% | Bullish | |
| $55.14 | $74.23 | $107.67 | +54% | Bullish | |
| $54.74 | $75.01 | $111.06 | +56% | Bullish | |
| $55.90 | $77.89 | $117.48 | +62% | Bullish | |
| $57.19 | $80.94 | $124.13 | +68% | Bullish | |
| $57.42 | $82.48 | $128.46 | +72% | Bullish | |
| $64.61 | $94.14 | $148.73 | +96% | Bullish | |
| $80.82 | $125.61 | $210.76 | +161% | Bullish | |
| $142.29 | $247.07 | $452.69 | +414% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $43.30 | $48.09 | $56.28 | +0.00% |
| June 2026 | $40.98 | $48.10 | $57.77 | +0.01% |
| July 2026 | $41.89 | $49.57 | $60.34 | +3.08% |
| August 2026 | $41.39 | $49.29 | $60.60 | -0.57% |
| September 2026 | $40.36 | $48.33 | $59.90 | -1.96% |
| October 2026 | $40.75 | $49.03 | $61.23 | +1.46% |
| November 2026 | $40.82 | $49.33 | $62.00 | +0.60% |
| December 2026 | $39.23 | $47.59 | $60.19 | -3.51% |
Click any year to see its month-by-month TECH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TECH is projected to trade between $43.30 and $60.19, averaging $48.09 — a potential gain of 0% from today's $48.09. A consolidation phase looks the most probable path here.
Bio-Techne Corporation's 2027 outlook centres on $50.64, within a $40.27 to $67.42 range. That is up +5% on the projected 2026 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2028, TECH could reach as high as $77.59, with a base case around $56.29 and support toward $43.59 — roughly +17% from $48.09. A consolidation phase looks the most probable path here.
Expect TECH to range from $49.77 to $93.10 through 2029. The $65.70 average target implies a +37% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The TECH price prediction for 2030 points to an average of $74.23 (low $55.14, high $107.67) — a potential gain of +54% on today's $48.09. Buyers look set to stay in control over this stretch.
In 2031, TECH is projected to trade between $54.74 and $111.06, averaging $75.01 — a potential gain of +56% from today's $48.09. That is up +1% on the projected 2030 average. Momentum favours further upside here.
Bio-Techne Corporation's 2032 outlook centres on $77.89, within a $55.90 to $117.48 range. That is up +4% on the projected 2031 average. That marks a +62% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TECH could reach as high as $124.13, with a base case around $80.94 and support toward $57.19 — roughly +68% from $48.09. Momentum favours further upside here.
Expect TECH to range from $57.42 to $128.46 through 2034. The $82.48 average target implies a +72% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TECH price prediction for 2035 points to an average of $94.14 (low $64.61, high $148.73) — a potential gain of +96% on today's $48.09. Momentum favours further upside here.
In 2040, TECH is projected to trade between $80.82 and $210.76, averaging $125.61 — a potential gain of +161% from today's $48.09. That is up +33% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Bio-Techne Corporation's 2050 outlook centres on $247.07, within a $142.29 to $452.69 range. That is up +97% on the projected 2040 average. That marks a +414% change versus current levels. Momentum favours further upside here.
Investing $1,000 in TECH today (≈ 20.794344 TECH) could be worth
$5,137.69
+$4,137.69 (+414%) by 2050 · US Dollar
Based on the average projected TECH price of $247.07 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TECHwould be worth at today's price.
$1,000 invested in TECH on May 27, 2025 (≈ 20.538099 TECH) would be worth
$987.68
-$12.32 (-1.2%) today · 0.99× · US Dollar
Based on a TECH entry price of $48.69 vs. today's $48.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $46.7 | $1,029.76 | +3.0% |
| 1 month ago | $55.11 | $872.62 | -12.7% |
| 3 months ago | $57.92 | $830.28 | -17.0% |
| 6 months ago | $64.51 | $745.47 | -25.5% |
| 1 year ago | $48.69 | $987.68 | -1.2% |
| All time (5.0y) ago | $102.56 | $468.9 | -53.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TECH forecast.
Our base-case forecast reaches $96.00 around 2040.
Implied market cap at $96.00: $15.03B
The multi-year forecast shows a bullish trajectory, with the average price rising from $48.21 in 2026 to $262.02 by 2050. The year-by-year averages include 2026 $48.21, 2027 $51.37, 2028 $57.71, 2029 $67.55, 2030 $77.13, 2031 $77.56, 2032 $80.35, 2033 $84.46, 2034 $85.48, 2035 $98.67, 2040 $132.05, and 2050 $262.02.
ROI increases along the path: 0% in 2026, 6.6% in 2027, 19.7% in 2028, 40.1% in 2029, 60% in 2030, 60.9% in 2031, 66.7% in 2032, 75.2% in 2033, 77.3% in 2034, 104.7% in 2035, 173.9% in 2040, and 443.5% in 2050. Sentiment shifts to BULLISH from 2029 onward.
These are forward-looking estimates and not guarantees; real results may differ due to market conditions, regulatory developments, and other uncertainties.
Tap a question to reveal the answer.
The forecast lists min $56.66, avg $77.13, max $113.33, with an ROI of 60% and sentiment BULLISH.
Forecasts show a bullish long-term path, with 2029 average $67.55 and 2050 average $262.02, and ROI rising to 443.5% by 2050; however these are estimates and not guarantees.
Yes. The forecast max by 2035 is $158.53, with earlier year maxs such as 2030 $113.33 and 2033 $131.54, indicating potential to exceed $100 in the mid-2030s; sentiment is BULLISH.
The 30-day snapshot shows min $43.30, avg $48.21, max $60.33; ROI 0%; sentiment NEUTRAL. The 30-day range is $40.01 to $58.08.
For 2031, min $55.90, avg $77.56, max $116.44, ROI 60.9%, sentiment BULLISH.
Bio-Techne Corporation Community Discussion
0Share your Bio-Techne Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.